drugset
Drugs / ChAd-triCoV/Mac
last change Jan 2025 re-read 3 minutes ago

ChAd-triCoV/Mac

Vaccine

Developed for
COVID-19
Investigated by
Canadian Institutes of Health Research (CIHR) · McMaster University

Trials 1

today NCT05094609 · Ph 1
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05094609 Jan 2022 → Jan 2025 COVID-19 McMaster University Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as ChAd-triCoV/Mac ClinicalTrials.gov intervention name — accepted as the source's own label NCT05094609 ↗
Modality Vaccine “new experimental adenovirus-based vaccines expressing SARS-CoV-2 spike, nucleocapsid and RNA polymerase proteins.” NCT05094609 ↗
Route Inhaled “Single dose by inhalation of 10e5 ChAd-triCoV/Mac” NCT05094609 ↗